Compounding, Insurance and White Paper - Pharmacy Technician Pulse

Compounding

Insurance

White Paper

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

JUNE 12, 2025

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Health and Personal Care Stores

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Insurance Coverage

MetrioPharm gains orphan drug status from EMA for MP1032

Pharmaceutical Technology

JULY 30, 2025

MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular dystrophy (DMD) in children. July 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook MP1032 is intended for treating Duchenne muscular dystrophy.

Packaging

Packaging Communication Immunization FDA

Join 5,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

HS market forecast to reach $7.8bn across 7MM by 2034

Pharmaceutical Technology

JULY 28, 2025

compound annual growth rate (CAGR) is largely attributed to the launch of novel biologics and small molecules targeting multiple inflammatory pathways beyond TNF-alpha inhibition. CAGR is largely attributed to the launch of novel biologics and small molecules. Give your business an edge with our leading industry insights.

Packaging

Packaging Communication Hospitals Compounding

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

JUNE 6, 2025

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Juvenescence CBE and CEO Dr Richard Marshall stated: “We are delighted to welcome the Ro5 team and the company’s capabilities into Juvenescence.

Communication

Communication Hospitals Packaging Compounding

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

JULY 22, 2025

Find out more J&J holds exclusive worldwide rights to advance icotrokinra through Phase II clinical trials and beyond, as well as to commercialise any compounds resulting from the research for a wide array of indications. Give your business an edge with our leading industry insights.

FDA

FDA Immunization Packaging Communication

MAXONA Pharma seeks FDA approval for pain relief MAX-001

Pharmaceutical Technology

AUGUST 8, 2025

MAXONA Pharmaceuticals has submitted an investigational new drug (IND) application seeking approval from the US Food and Drug Administration (FDA) for its lead compound, MAX-001, to treat acute pain. Give your business an edge with our leading industry insights.

FDA

FDA Packaging Compounding Communication

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

JUNE 24, 2025

Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.

Compounding

Compounding Packaging Communication FDA

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

JUNE 19, 2025

These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026.

Communication

Communication Hospitals Packaging Compounding

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

JUNE 12, 2025

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Give your business an edge with our leading industry insights.

Compounding

Compounding Communication Hospitals Packaging

Atombeat and BioDuro link for peptide drug discovery platform

Pharmaceutical Technology

AUGUST 4, 2025

These tools enable the exploration of a digital library with over one trillion potential peptide compounds, streamlining the early drug discovery process. By GlobalData Learn more about Strategic Intelligence BioDuro’s role in the partnership is to leverage its synthesis capability for producing several peptide compounds in parallel.

Compounding

Compounding Communication Hospitals Packaging

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Pharmaceutical Technology

JUNE 18, 2025

It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Compounding

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

JUNE 30, 2025

The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bird’s-eye view of the current Vetter site in Des Plaines where the clinical manufacturing facility will be built.

Packaging

Packaging Compounding Hospitals Communication

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

Pharmaceutical Technology

JUNE 13, 2025

CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Vaccines Packaging

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

Pharmaceutical Technology

AUGUST 6, 2025

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide, an active ingredient in its weight-loss and diabetes drugs, Wegovy and Ozempic, respectively. The FDA has issued several alerts, including one on 29 July, warning about the dangers of these knockoff drugs.

Compounding

Compounding Packaging FDA Communication

Why can’t the US figure out weight loss drug prices?

Pharmaceutical Technology

JUNE 27, 2025

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.

Compounding

Compounding Packaging FDA Communication

Novo Nordisk teams up with WeightWatchers in latest telehealth push

Pharmaceutical Technology

JUNE 27, 2025

In March 2025, Novo Nordisk discounted the cost of all doses to $499 per month to competitively price its prized asset against cheaper compounded alternatives. Compounded semaglutide is a personalised weight loss medicine, which is chemically identical to branded alternatives.

Compounding

Compounding Packaging FDA Communication

Novo Nordisk’s diabetes and weight loss drug sales growth decelerates

Pharmaceutical Technology

AUGUST 6, 2025

By GlobalData Learn more about Strategic Intelligence Lower sales have not solely been caused by Eli Lilly – the rise in compounded semaglutide has been a big cause of concern for Novo Nordisk. The company has maintained that continued compounding is unlawful and unsafe. Stay proactive with real-time data and expert analysis.

Compounding

Compounding Packaging Communication Hospitals

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Pharmaceutical Technology

JUNE 13, 2025

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is poised to grow at a compound annual growth rate of 5.3% Credit: Vitalii Vodolazskyi via Shutterstock. billion in 2024 to $10.3 Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Vaccines Packaging

Pulmonary arterial hypertension market to reach $9.35bn across 7MM by 2034

Pharmaceutical Technology

JULY 8, 2025

The pulmonary arterial hypertension (PAH) market is forecast to grow at a compound annual growth rate (CAGR) of 2.0% Symptoms such as fatigue, breathlessness, and chest pain are frequently misattributed to more common conditions, delaying intervention and compounding disease burden. Credit: Green Apple via Shutterstock.

Packaging

Packaging Hospitals Compounding Communication

Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO

Pharmaceutical Technology

JULY 30, 2025

By GlobalData Learn more about Strategic Intelligence Lower sales have not solely been caused by Eli Lilly – the rise in compounded semaglutide has eroded market share for Novo Nordisk. The company has maintained that continued compounding is unlawful and unsafe. Give your business an edge with our leading industry insights.

Compounding

Compounding Packaging Communication Hospitals

CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031

Pharmaceutical Technology

JULY 10, 2025

Ross Law July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The global oncology market is set to grow at a compound annual growth rate (CAGR) of 24.5%. Image credit: CI Photos / Shutterstock. Give your business an edge with our leading industry insights.

Packaging

Packaging Hospitals Compounding Communication

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

MetrioPharm gains orphan drug status from EMA for MP1032

Trending Sources

HS market forecast to reach $7.8bn across 7MM by 2034

Juvenescence enhances AI drug discovery with Ro5 acquisition

J&J seeks FDA approval for icotrokinra to treat psoriasis

MAXONA Pharma seeks FDA approval for pain relief MAX-001

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Draig secures $140m for neuropsychiatric disorder therapies

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Atombeat and BioDuro link for peptide drug discovery platform

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Vetter breaks ground on $285m US clinical manufacturing site

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

Why can’t the US figure out weight loss drug prices?

Novo Nordisk teams up with WeightWatchers in latest telehealth push

Novo Nordisk’s diabetes and weight loss drug sales growth decelerates

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Pulmonary arterial hypertension market to reach $9.35bn across 7MM by 2034

Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO

CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031

Stay Connected